MORE►
AyuVis
Dr. Suchismita Acharya, co-founder and CEO of AyuVis [Photo: AyuVis]
Fort Worth’s AyuVis Receives $2.1M NIH Grant for Clinical Trial of New-Gen Immunotherapies
by Lance Murray | May 17, 2023
The grant from the National Heart, Lung, and Blood Institute will fund a first-in-human Phase 1 clinical trial of a new generation of immunotherapies. This is the fourth NIH grant AyuVis has received since its founding in 2014, doubling total non-dilutive funding to $4.2 million. Co-Founder and CEO Dr. Suchismita Acharya calls the move to a human trial "a huge milestone for AyuVis."
by Kevin Cummings |
May 17, 2022
What companies are finding funding or having a big exit? From startup investments to grants and acquisitions, Dallas Innovates tracks what’s happening in North Texas money.
MORE►
by Kevin Cummings |
May 12, 2022
AyuVis, an immunotherapy startup, is set to get a $1.8 million Small Business Innovation Research grant from the Eunice Kennedy Shriver National Institute of Child Health and Human Development. The funding will support the pre-clinical research of its drug candidate to treat the second-leading cause of death in premature babies.
Founder Suchismita Acharya calls the timing "perfect."
Founder Suchismita Acharya calls the timing "perfect."
MORE►
by David Kirkpatrick |
Mar 31, 2022
Fort Worth-based AyuVis just received its second patent in three months for its immunotherapy treatments that protect pre-term babies from a debilitating chronic lung disease that affects many pre-term infants on ventilators.
The startup's lead drug candidate—AVR-48—is scheduled for clinical trials this summer.
The startup's lead drug candidate—AVR-48—is scheduled for clinical trials this summer.
MORE►
